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French chemist isolates phlorizin from apple tree bark
Joseph von Mering demostrates that ingestion of
high doses of phlorizin causes glycosuria
First-in-human testing of phlorizin
Discovery of tissue distribution of SGLT1/2
Phlorizin inhibits SGLT1 and SGLT2
First SGLT2 inhibitor FDA approved
First dual SGLT1/2 inhibitor
pending approval

















































PGC = pressure in glomerular capillary




















































































































Effects of Canagliflozin on Cardiovascular, Kidney,  Hospitalization, 
and Death Events in the Integrated CANVAS Program. 
Hospitalization	for	
Heart	Failure		
33%	relative	risk	
reduction	
Progression	of	
albuminuria		
27%	relative	risk	
reduction		
Composite	kidney	
outcome	(40%	
reduction	in	eGFR,	
RRT,	Death	from	
Kidney	causes	
40	%	relative	risk	
reduction		
